MAP Pharmaceuticals To Present MAP0004 Phase 2 Clinical Data At The American Headache Society Meeting
MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its MAP0004 migraine therapy clinical program at the 49th Annual American Headache Society Meeting at the Hyatt Regency Chicago in Chicago, Illinois.
